KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short term Debt (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Short term Debt for 9 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt fell 34.41% to $31.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.1 million, a 34.41% decrease, with the full-year FY2025 number at $31.1 million, down 34.41% from a year prior.
  • Short term Debt was $31.1 million for Q4 2025 at Supernus Pharmaceuticals, up from $11.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $401.4 million in Q3 2022 to a low of $11.2 million in Q3 2025.
  • A 5-year average of $58.0 million and a median of $45.9 million in 2023 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: soared 1603.17% in 2022, then tumbled 88.57% in 2023.
  • Supernus Pharmaceuticals' Short term Debt stood at $44.8 million in 2021, then plummeted by 52.9% to $21.1 million in 2022, then skyrocketed by 146.54% to $52.1 million in 2023, then decreased by 9.08% to $47.3 million in 2024, then tumbled by 34.41% to $31.1 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Short term Debt are $31.1 million (Q4 2025), $11.2 million (Q3 2025), and $30.0 million (Q1 2025).